Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial

Plouin, Pierre‐François; Breart, Gérard; Maillard, Florie; Papiernik, E; Relier, Jean-Pierre

doi:10.1111/j.1471-0528.1988.tb06571.x

Cited by 81 publications

(34 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4 In Verma et al, study Mean birth weight of Methyldopa group was more than Labetolol group. 5 The Mean birth weight of the present study was also comparable with the studies of Plouin et al, Lamming et al 6,7 Apgar score…”

Section: Discussionsupporting

confidence: 81%

Effect of methyldopa and labetolol on fetal outcomes in hypertensive disorders of pregnancy

Pentareddy

Shailendra

2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Hypertensive disorders represent the most common medical complication of pregnancy, with a reported incidence of 6-10% and accounts for 15% of maternal mortality. Effective management of pregnancy induced hypertension is vital to improve maternal and foetal outcomes. As data are scarce on comparison of labetolol and methyldopa this study was undertaken. The objectives of the study were to evaluate effect of both drugs on fetal outcomes.Methods: A comparative observational Study is designed. 30 patients who received Methyldopa and 30 patients who received Labetolol were included in the study. Methyldopa was started at a dose of 250-500mg thrice daily while Labetolol was started at a dose of 100-400mg twice daily. Patients were followed up during antenatal, intrapartum and postpartum period for perinatal outcomes.Results: Intra Uterine Growth Retarded (IUGR) babies were 10% in Methyldopa group and 6.66% in Labetolol group. 20% of new borns in Methyldopa group and 10% of new borns in Labetolol group got admitted in Neonatal Intensive Care Unit (NICU) because of distress. 13.3% of new borns in Methyldopa group are small for gestational age(SGA), whereas only 3.33% in Labetolol group are small for gestational age.Conclusions: Chances of development of IUGR, NICU admissions of neonates with respiratory distress syndrome and small for gestational age babies were more with methyldopa compared to Labetolol, but there was no statistically significant difference between two drugs.

show abstract

Section: Discussionsupporting

confidence: 81%

Effect of methyldopa and labetolol on fetal outcomes in hypertensive disorders of pregnancy

Pentareddy

Shailendra

2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…This study was also comparable with previous studies Redman et al, Sibai et al, Plouin et al, Pickles et al, Sibai BM et al [6][7][8][9][10] However, few studies say that labetalol provides more efficient control of BP than methyldopa in the treatment of mild hypertension in pregnancy.…”

Section: Discussionsupporting

confidence: 81%

Safety and efficacy of methyldopa and labetalol in controlling blood pressure in hypertensive disorders of pregnancy

Pentareddy

Shailendra

Prasuna

et al. 2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Hypertensive disorders represent the most common medical complication of pregnancy, with a reported incidence of 6-10% and accounts for 15% of maternal mortality. Effective management of pregnancy induced hypertension is vital to improve maternal and foetal outcomes. As data are scarce on comparison of labetolol and methyldopa this study was undertaken. The objective of present study is compare the efficacy and safety of Labetalol versus Methyldopa in the management of Mild to Moderate pregnancy induced hypertension. To evaluate effect of both drugs on maternal and foetal outcomes.Methods: A comparative observational study is designed. 30 patients who received methyldopa and 30 patients who received labetalol were included in the study. Methyldopa was started at a dose of 250-500 mg thrice daily while labetalol was started at a dose of 100-400 mg twice daily. Patients were followed up during antenatal, intrapartum and postpartum period for efficacy, safety, maternal, and perinatal outcomes.Results: Methyldopa and Labetalol reduced mean systolic and mean diastolic blood pressures significantly. safety profile of both drugs was similar. Spontaneous vaginal deliveries were observed more with labetolol significantly.Conclusions: Labetalol is equally efficacious as methyldopa and well tolerated in the treatment of new onset hypertension during pregnancy.

show abstract

“…There were a total of 3 neonatl deaths, 2 (5%) in methyldopa group and 1 (2.5%) in labetalol group; controversaly, Plouin et al [31] made a findings and our report were not in corroboration with his report. He also demonstrated that four still births in methyldopa group.…”

Section: Discussioncontrasting

confidence: 56%

“…The rest of the patients were multigravidae. However the percentage of primigravidae is greater in most other studies where the prevalence of primigravidae was 50% or above [30,31].…”

Section: Discussionmentioning

confidence: 71%

Study of Methyl Dopa Versus Labetalol in Management of Preeclampsia and Gestational Hypertension

MK¹

2014

Gynecol Obstet (sunnyvale)

View full text Add to dashboard Cite

Objective: To assess the efficacy and safety of labetalol compared with methyldopa in the management of mild and moderate cases of pregnancy-induced hypertension (PIH).Methods: Eighty patients with PIH were randomly allocated to receive either labetalol (group A) or methyldopa (group B). Administration of drugs with respect to Age, Gravid Status, Blood Pressure, Urine albumin Levels, Side Effects, Drug dosage, Additional Treatment, Prolongation of Pregnancy, New born Screening Test (NST), mode of termination, Indication of caesarean section, Perinatal safety and APGAR scores were studied. The statistical level of significance was taken at P<0.05. Results:A labetalol has been very effective in control as well as earlier onset of action in patients with methyl dopa. With effective control of blood pressure, prevention of eclampsia and the pregnancy can be prolonged to achieve fetal maturity. Labetalol has lesser side effects when compared to methyldopa. Labetalol is not associated with adverse fetal effects in the immediate and late neonatal period. The chances of spontaneous onset of labor were greater in the labetalol group when compared to methyldopa group. Though there was no difference in the groups with regard to obstetric intervention. At clinically effective doses, both the drugs were found to be safe for the neonate. Conclusions:Labetalol is safer, quicker in achieving adequate control of blood pressure with considerable prolongation of the duration of pregnancy with fewer side effects on the mother as well as the neonate when used in the management hypertensive disorders of pregnancy.

show abstract

Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial

Cited by 81 publications

References 16 publications

Effect of methyldopa and labetolol on fetal outcomes in hypertensive disorders of pregnancy

Effect of methyldopa and labetolol on fetal outcomes in hypertensive disorders of pregnancy

Safety and efficacy of methyldopa and labetalol in controlling blood pressure in hypertensive disorders of pregnancy

Study of Methyl Dopa Versus Labetalol in Management of Preeclampsia and Gestational Hypertension

Contact Info

Product

Resources

About